As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/enfortumab-vedotin-pembro-beats-cisplatin-resectable-mibc-2026a10006gl?src=rss
Author :
Publish date : 2026-03-02 18:21:00
Copyright for syndicated content belongs to the linked Source.